We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with type 2 diabetes did not have higher risk for ...
TOKYO, June 5 (Reuters) - A drug candidate critical to Takeda Pharmaceutical Co Ltd's <4502.T> mainstay diabetes franchise is expected to show sufficient promise to gain approval but may not be much ...
A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor. Results: Initially, more than 50% of ...
SaveHealth reports on managing type 2 diabetes through medications, lifestyle changes, and support, highlighting various ...
NEW YORK (Reuters) - GlaxoSmithKline Plc will study combining its diabetes drug Avandia with a new class of DPP-4 medicines but does not believe its established drug is under threat, its chief ...
For patients with diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) don’t appear to increase suicidality over what’s seen with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback